"10.1371_journal.pone.0079022","plos one","2013-11-18T00:00:00Z","Michael G Schwendinger; Maria O'Rourke; Andreas Traweger; Helga Savidis-Dacho; Andreas Pilz; Daniel Portsmouth; Ian Livey; P Noel Barrett; Brian A Crowe","Vaccine R&D, Baxter BioScience, Orth/Donau, Austria","Conceived and designed the experiments: MGS MO AT AP IL PNB BAC. Performed the experiments: MGS MO AT HSD AP. Analyzed the data: MGS MO AT HSD AP DP IL PNB BAC. Wrote the paper: MGS MO AT HSD AP DP IL PNB BAC.","This study was funded by Baxter. All authors are current or previous employees of Baxter. M.G.S., M.O.R., H.S.D., I.L., P.N.B. and B.A.C. report having an equity interest in the company. Brian A. Crowe, Ian Livey, Maria ORourke and P. Noel Barrett are named as inventors on patents and patent applications related to the manufacture of recombinant OspA vaccines to prevent Lyme borreliosis: Chimeric OspA genes, proteins, and methods of use thereof. Livey I, ORourke M, Schwendinger M, Crowe BA; Patent No: US 2011/0293652; US 2012/0020973; EP 2 569 009 (WO 2011/143617); EP 2 569 008 (WO 2011/143623); JP 2013-529-077; JP 2013-529078. Composition comprising chimeric OspA molecules and methods of use thereof; Barrett PN, Aichinger G, Crowe BA, Livey I, Wressnig N; Patent filed: PCT US 13/50058; US filed 13/939759. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Michael G Schwendinger","MGS",9,TRUE,7,5,9,9,TRUE,TRUE,FALSE,0,NA,FALSE
